Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy


You May Also Like

Sunesis Announces Pricing of $20 Million Offering of Securities

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) ...

American College of Rheumatology Wins 2016 ASAE Gold Circle Award

ATLANTA, May 5, 2016 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) has ...